drugset / Trial / NCT06327815
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
RandomizedParallel-groupOpen-labelTreatment
Summary
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM.
Timeline
- Start
- 2024-03-15
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Publications
- Background Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence. 2016 Aug 16;10:1573-81. doi: 10.2147/PPA.S107543. eCollection 2016.
- Background Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012 Jun;28(6):969-77. doi: 10.1185/03007995.2012.684045. Epub 2012 May 3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Metformin | Small molecule | 1000 mg | — |
| Subject | Xigduo | Unknown | 10 mg | — |
| Subject | Xigduo | Unknown | 1000 mg | — |